How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach

INTRODUCTION: ) and subsequent treatment success (SALT score ≤ 20) in four subgroups defined by baseline disease severity and AA episode duration to inform the treatment length required before assessing failure, based on disease presentation. METHODS: and subsequent SALT score ≤ 20 over time. RESULTS: achieved in 42%/25% of patients by Week 24, leading to SALT score ≤ 20 in 58%/43% at Week 52, respectively. CONCLUSIONS: increased through Week 52; therefore, treatment should be given for ≥ 1 year before assessing treatment failure.

Authors

Institutions

Publication Details

Journal
Dermatology and Therapy
Published
2026-04-16
DOI
https://doi.org/10.1007/s13555-026-01723-z
Primary Topic
Hair Growth and Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach

Manabu Ohyama, Bianca Maria Piraccini, Najwa Somani, King Bl et al.
Dermatology and Therapy
Hair Growth and Disorders
article

How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach

Manabu Ohyama, Bianca Maria Piraccini, Najwa Somani, King Bl, Yun-Fei Chen, Rodney Sinclair, Andrew Buchanan, Jakub Jedynak, Na Lu, Maryanne Senna
article en

Abstract

INTRODUCTION: ) and subsequent treatment success (SALT score ≤ 20) in four subgroups defined by baseline disease severity and AA episode duration to inform the treatment length required before assessing failure, based on disease presentation. METHODS: and subsequent SALT score ≤ 20 over time. RESULTS: achieved in 42%/25% of patients by Week 24, leading to SALT score ≤ 20 in 58%/43% at Week 52, respectively. CONCLUSIONS: increased through Week 52; therefore, treatment should be given for ≥ 1 year before assessing treatment failure.

Dermatology and Therapy
Lahey Hospital and Medical Center (US), Eli Lilly (United States) (US), Kyorin University (JP), Yale University (US), Sinclair Dermatology (AU), University of Bologna (IT)
Eli Lilly and Company, Incyte
Good health and well-being
Openalex Percentile: Top 19%
Hair Growth and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach — Manabu Ohyama, Bianca Maria Piraccini, et al. · Dermatology and Therapy (2026) | TGRS Research Map | TGRS